Shionogi & Co., Ltd. 4507

Shionogi & Co Ltd (SGIOF) recently announced a total dividend of $0.24 per share, with the ex-dividend date set for 2026-09-29. This upcoming payment includes a $0.24 per share cash dividend, though the payable date is currently listed as 0000-00-00, indicating that the specific payment date has not yet been confirmed in the available data. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.

FLORHAM PARK, N.J., September 09, 2026--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will present findings from across its broad anti-infective portfolio at IDWeek 2026 (October 21-24, 2026), in Washington, D.C.

OSAKA, Japan, August 28, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that the Biomedical Advanced Research and Development Authority (BARDA) has exercised a $36.9 million procurement option, under Project BioShield funding, from its April 2026 contract with Shionogi Inc., a New Jersey-based subsidiary of Shionogi, to procure Fetroja® (cefiderocol) as a critical countermeasure against difficult-to-treat Gra

FLORHAM PARK, N.J., July 30, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter, "Shionogi") today announced the four-year anniversary of RADICAVA ORS® (edaravone), the only oral formulation of edaravone approved by the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS).

LONDON, July 29, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced data to be presented this week at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil. Multiple studies span long-term outcomes, real-world use, injection experience, adherence and future long-acting options for HIV treatment and prevention.

LONDON, July 21, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced new clinical and real-world data highlighting its integrase strand transfer inhibitor (INSTI)-focused portfolio, including long-acting (LA) medicines and pipeline momentum, to be presented at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil, from 26-31 July.

Shionogi & Co. (SGIOY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

– Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan – – Verrica maintains ownership of global rights to YCANTH for all indications in all territories outside of Japan, including common warts – WEST CHESTER, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatol

Shionogi (TSE:4507) has just received U.S. FDA approval for XOCOVA (ensitrelvir) as an oral post exposure prophylaxis for COVID-19 in adults and adolescents, marking the first approved drug of its kind globally. See our latest analysis for Shionogi. Despite the FDA approval for XOCOVA and recent launches such as the EndeavorRide ADHD support app, Shionogi’s share price return has fallen 17.82% over the past 90 days, although the 1-year total shareholder return of 13.85% and 5-year total...

TOKYO, June 09, 2026--Rigaku Corporation, a global solution partner in X-ray analytical systems and a group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; "Rigaku"), announced that the results of a joint research project conducted with Shionogi & Co., Ltd., JEOL Ltd., and Meiji Pharmaceutical University have been published in Crystal Growth & Design, a world-renowned international journal in the field of crystallography.

OSAKA, Japan, June 01, 2026--Shionogi Announces FDA Approval of XOCOVA® (ensitrelvir), the First and Only Oral Option to Help Prevent COVID-19 Following Exposure

DURHAM, N.C., June 01, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the launch of its PrEP Wisdom campaign, designed to empower people to make informed decisions about long-acting injectable (LAI) HIV prevention, beyond the dosing schedules. The campaign features TV personality Michelle Visage, a long-time HIV and LGBTQ advocate.

D-Wave Quantum (QBTS) president and CEO Alan Baratz sits down with Yahoo Finance Executive Editor Brian Sozzi to discuss Nvidia's (NVDA) artificial intelligence (AI) models for quantum computing, the future of the industry, and more.

Shionogi has received a major U.S. government contract to manufacture its antibiotic Fetroja domestically. New real world clinical data supports Fetroja's effectiveness and safety against high priority multidrug resistant bacterial pathogens. These developments signal a step up in Shionogi's U.S. presence in antibiotics targeting drug resistant infections. For investors watching Shionogi, ticker TSE:4507, the combination of a U.S. government manufacturing contract and fresh clinical support...

The newly published charter widens the required expertise to become an ACIP member and stresses vaccine safety. Elsewhere, Gilead licensed a Kymera drug and a new RNA-focused startup emerged.

This funding will boost the US’s antibiotic manufacturing capacity, while helping to curb the threat of antimicrobial resistance (AMR) across America.